SS-31 (Elamipretide)
SS-31 (Elamipretide) scored 6.0 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Peptide → Other Peptide.
SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide that binds cardiolipin. Karaa 2023 found no broad PMM benefit in MMPOWER-3, while FDA granted accelerated Forzinity approval for Barth syndrome in patients weighing at least 30 kg.
What is SS-31 (Elamipretide)?
SS-31, now known clinically as elamipretide and marketed as Forzinity for Barth syndrome, is a mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane. Cardiolipin helps organize mitochondrial cristae, the folds where electron transport chain complexes sit and ATP is produced. Birk 2013 showed SS-31 interacting with cardiolipin in ischemic mitochondria, while Szeto 2014 framed the compound as the lead cardiolipin-protective peptide in the Szeto-Schiller class.
The clinical story is narrower than the mechanism sounds. Karaa 2018 showed a short-term 6-minute walk signal in a small primary mitochondrial myopathy trial, but the larger Karaa 2023 MMPOWER-3 trial missed the 6-minute walk and fatigue co-primary endpoints. Ehlers 2024 ReCLAIM-2 also missed primary endpoints in dry AMD, even though exploratory retinal-structure and vision signals remained interesting. Karaa 2024 then suggested genotype-defined PMM subgroups may respond better, but that was post hoc.
The practical v1.0 read: SS-31 is no longer just a speculative research peptide because FDA granted accelerated approval to Forzinity on September 19, 2025 for Barth syndrome patients weighing at least 30 kg. But that approval is not a blank check for longevity, healthy biohacking, AMD, heart failure, primary mitochondrial myopathy, cognition, or athletic performance. It is a narrow prescription use built around a rare disease where cardiolipin remodeling is genetically broken.
Terminology
For the prescription context, see the Forzinity prescribing information.
- SS-31: Original research name for the Szeto-Schiller peptide 31, the mitochondria-targeting tetrapeptide now known as elamipretide.
- Elamipretide: International nonproprietary name for SS-31, formerly MTP-131 and Bendavia. Marketed as Forzinity for Barth syndrome.
- Forzinity: FDA-approved prescription elamipretide injection for improving muscle strength in Barth syndrome patients weighing at least 30 kg.
- Cardiolipin: Signature phospholipid of the inner mitochondrial membrane. It stabilizes cristae architecture and electron transport chain supercomplexes.
- ETC: Electron transport chain, the mitochondrial enzyme complexes that transfer electrons and help generate ATP.
- ATP: Adenosine triphosphate, the cell's usable energy currency.
- ROS: Reactive oxygen species. In excess, mitochondrial ROS can damage cardiolipin and worsen electron leak.
- Barth syndrome: Rare X-linked mitochondrial disease caused by pathogenic variants in TAFAZZIN, producing cardiolipin remodeling failure, cardiomyopathy, skeletal myopathy, neutropenia, and growth issues.
- TAFAZZIN: The gene disrupted in Barth syndrome. It encodes the enzyme needed for normal cardiolipin remodeling.
- PMM: Primary mitochondrial myopathy, a genetically heterogeneous group of mitochondrial muscle diseases.
- IND: Investigational New Drug pathway that permits clinical investigation of an unapproved agent.
- CRL: Complete Response Letter, an FDA communication that a drug application is not approvable in its current form.
- 6MWT: Six-Minute Walk Test, a functional endpoint measuring how far a patient can walk in six minutes.
- TAZPOWER: Barth syndrome trial program of elamipretide, including randomized crossover and open-label extension phases.
- MMPOWER-3: Phase 3 primary mitochondrial myopathy trial of elamipretide. Karaa 2023 reported missed co-primary endpoints.
- PROGRESS-HF: Phase 2 heart-failure trial of elamipretide. Butler 2020 reported no LVESV benefit.
- ReCLAIM-2: Phase 2 dry AMD trial of elamipretide. Ehlers 2024 reported missed primary endpoints.
- HFrEF: Heart failure with reduced ejection fraction.
- LVESVi: Left ventricular end-systolic volume index, a measure of chamber size after contraction.
- Injection-site reaction: Redness, swelling, itching, bruising, hives, or pain around the subcutaneous injection site.
- FAERS: FDA Adverse Event Reporting System, the spontaneous post-market safety-reporting database.
How do you take SS-31 (Elamipretide)?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous injection (gray-market elamipretide) | Lyophilized peptide reconstituted in bacteriostatic water | N/A (unapproved channel) | 5-10 mg/day, occasionally 10-20 mg/day in cycling protocols |
| Subcutaneous injection (Forzinity / trial-grade elamipretide) | Sterile prescription injection or trial-grade product | 40 mg/day subcutaneous for Barth syndrome patients weighing at least 30 kg; 20 mg/day in adults with severe renal impairment not on dialysis per label dosing | N/A |
| Intravenous infusion (trial only) | IV infusion | 0.005-0.25 mg/kg/hour in acute heart-failure dose-ranging work | N/A |
Protocols
Longevity biohacker (gray-market) Anecdotal
- Dose
- 5-10 mg/day subcutaneous
- Frequency
- Daily
- Duration
- 12 weeks on / 4 weeks off is a common cycling pattern
Cost-driven underdosing versus clinical 40 mg/day. No RCT evidence at this dose.
Barth syndrome (FDA-approved Forzinity) Clinical
- Dose
- 40 mg subcutaneous
- Frequency
- Daily
- Duration
- Continuous
FDA accelerated approval is based on improved knee extensor muscle strength as an intermediate endpoint, with confirmatory clinical-benefit verification still required.
MMPOWER-3 (primary mitochondrial myopathy) Clinical
- Dose
- 40 mg subcutaneous
- Frequency
- Daily
- Duration
- 24 weeks
[Karaa 2023](https://pubmed.ncbi.nlm.nih.gov/37268435/) missed 6MWT and fatigue co-primary endpoints in n=218 genetically confirmed PMM patients.
Dry AMD ReCLAIM-2 protocol Clinical
- Dose
- 40 mg subcutaneous
- Frequency
- Daily
- Duration
- 48 weeks plus follow-up
[Ehlers 2024](https://pubmed.ncbi.nlm.nih.gov/39605874/) missed primary endpoints but showed exploratory ellipsoid-zone and low-luminance vision signals.
Cycling (harm-reduction) Anecdotal
- Dose
- 5-10 mg subcutaneous
- Frequency
- Daily during ON block
- Duration
- 12 weeks on, 4 weeks off
Rationale is cost management plus injection-site rotation. No clinical evidence shows that cycling improves or worsens outcomes.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
What are the benefits of SS-31 (Elamipretide)?
Upside contribution: 2.08
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.5 | 0.875 | |
| Breadth | 15% | 3.0 | 0.450 | |
| Evidence | 25% | 3.8 | 0.950 | |
| Speed | 10% | 2.0 | 0.200 | |
| Durability | 10% | 1.8 | 0.180 | |
| Bioindividuality | 15% | 2.8 | 0.420 | |
| Total | 3.075 |
Upside Rationale
SS-31 (elamipretide) is a genuinely efficacious compound where cardiolipin dysfunction is central, anchored by a real regulatory milestone rather than a mechanism story alone. The decisive fact is that FDA 2025 granted accelerated approval (Forzinity) for Barth syndrome on a measured strength endpoint, and Reid Thompson 2021 backs it with a 95.9-meter 6-minute-walk gain in open-label extension. That approval plus a coherent cardiolipin-stabilizing mechanism is why SS-31 (elamipretide) earns a solid efficacy mark, credited at real strength rather than deflated. Peripheral single-indication nulls in primary mitochondrial myopathy and geographic-atrophy AMD exist, but they mark where the molecule did not yet win, not a failure of the core. For a user with a clear cardiolipin-linked target, SS-31 (elamipretide) is a real intervention with proven human effect, not a blanket vitality claim.
SS-31 (elamipretide) acts on a broad mitochondrial mechanism, yet its proven clinical breadth stays concentrated. Cardiac, skeletal-muscle, renal, retinal, and neural tissue all depend on inner-membrane integrity, and SS-31 (elamipretide) binds cardiolipin to stabilize cristae across them. Birk 2013 supports the renal-ischemia mechanism, and acute heart-failure and AMD signals round out the tissue reach. But the only endpoints that crossed a regulatory line are Barth-specific. So the breadth of SS-31 (elamipretide) is real at the tissue-mechanism level and thinner at the level of demonstrated clinical outcomes, which is why its breadth score lands middling rather than high. A mechanism that touches every high-energy organ is promising, yet for this score what counts is where SS-31 (elamipretide) has actually moved a human endpoint, and that remains the cardiolipin core.
Evidence is the strongest pillar for SS-31 (elamipretide): a genuine multi-indication human-trial program plus a regulatory milestone, not a peptide resting on rodent data. The 2025 FDA accelerated approval of Forzinity for Barth syndrome is a verified real-world outcome that anchors the cardiolipin core, layered on mechanism papers and multiple randomized late-stage readouts. It holds just below the top band because the trial pattern is mixed: Karaa 2023 missed primaries in n=218 mitochondrial myopathy and Ehlers 2024 missed primary AMD endpoints. Those are peripheral, single-indication nulls rather than a refutation of SS-31 (elamipretide), so they are noted without dragging the core. The evidence on SS-31 (elamipretide) reads as substantial and credible but indication-specific, with the approved use carrying far more weight than the misses.
SS-31 (elamipretide) is slow for felt benefit, which limits its upside for users chasing a quick lift. The compound can shift mitochondrial physiology fast in controlled settings: Daubert 2017 saw acute cardiac-volume change after one IV infusion and Siegel 2013 moved aged-muscle ATP within an hour. But in real subcutaneous use, any user-perceived energy or cognition change typically takes two to four weeks, if it appears at all, and the meaningful clinical endpoints (6-minute walk, fatigue, muscle strength) are measured over months. That makes SS-31 (elamipretide) far slower to feel than creatine or stimulants, so its speed is a weak contributor to the overall case even though the underlying efficacy is real.
Durability is the weakest part of the SS-31 (elamipretide) upside. Benefit appears strictly exposure-dependent: the peptide has a short plasma half-life, daily dosing is standard, and no verified evidence shows lasting off-drug remodeling after a completed course. The Barth extension data describe maintenance while dosing continues, not a permanent reset. In practice, stopping SS-31 (elamipretide) lets cardiolipin stabilization and any subjective gain fade over days to weeks as drug clears. So SS-31 (elamipretide) buys a sustained-while-dosing effect, not a durable correction, and that fade is a central reason its cost-to-benefit is poor for healthy users rather than disease-indicated ones. Any user weighing SS-31 (elamipretide) should treat it as an open-ended commitment, not a one-time fix.
SS-31 (elamipretide) is strongly responder-dependent, so its upside concentrates in a defined subgroup. Barth syndrome is the best-characterized responder population because TAFAZZIN dysfunction maps directly onto the cardiolipin remodeling SS-31 (elamipretide) targets, which is exactly why the approved indication scores so well. Karaa 2024 suggests primary-mitochondrial-myopathy genotype may also matter, but that signal needs prospective confirmation. Older adults with objectively measured mitochondrial impairment are plausible candidates, not proven ones. Healthy users under 50 without documented mitochondrial dysfunction are weak candidates for SS-31 (elamipretide), and a neutral gray-market cycle in that group fits the low-responder profile. The practical filter is whether objective mitochondrial dysfunction is documented before any SS-31 (elamipretide) trial, because that single fact separates plausible responders from likely non-responders.
What are the risks & downsides of SS-31 (Elamipretide)?
Downside contribution: 1.26 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 2.0 | 0.600 | |
| Side effects | 15% | 2.2 | 0.330 | |
| Cost | 5% | 3.8 | 0.190 | |
| Effort | 5% | 3.2 | 0.160 | |
| Opportunity | 5% | 1.5 | 0.075 | |
| Dependency | 15% | 2.0 | 0.300 | |
| Reversibility | 25% | 1.3 | 0.325 | |
| Total | 1.980 | |||
| Harm subtotal × 1.4 | 2.177 | |||
| Opportunity subtotal × 1.0 | 0.425 | |||
| Combined downside | 2.602 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.262 |
Downside Rationale
SS-31 (elamipretide) carries a clean intrinsic safety profile for a peptide, so its real downside is sourcing and medical-fit, not systemic toxicity. FDA 2025 described mostly mild-to-moderate injection-site reactions in trials, with no drug-attributed death signal driving the assessment. The Forzinity label sets the real boundaries: serious hypersensitivity is a contraindication, with a benzyl-alcohol neonatal warning and renal dose adjustment in severe impairment. The separate and larger hazard for SS-31 (elamipretide) is the gray market, where contamination, mislabeling, underpotency, or poor sterility are the practical risks. That is a procurement problem, not proof the molecule itself is dangerous, so risk-tolerance for SS-31 (elamipretide) should drop sharply for pregnancy, complex histories, or unverified product.
The dominant real adverse event for SS-31 (elamipretide) is a localized injection-site reaction, not severe systemic harm, which is why its side-effect burden is low rather than alarming. Redness, swelling, itching, bruising, hives, induration, and pain at the site lead the profile. Ehlers 2024 reported adverse events more often with SS-31 (elamipretide) than placebo, mainly injection-site reactions. Headache, dizziness, nausea, and GI upset appear across the development program but are not the defining signal. The earlier higher concern was inflated; the honest read on SS-31 (elamipretide) is good tolerability with a daily-injection nuisance factor, where even mild local reactions can become disruptive simply because the injections recur every day.
Cost is a genuine downside for SS-31 (elamipretide) at any clinically meaningful exposure, and the approved channel makes that worse, not better. Gray-market protocols of 5 to 10 mg per day commonly run $200 to $500 per month, and higher daily doses can push monthly spend into the thousands without prescription coverage. Forzinity is priced and distributed like an ultra-rare-disease orphan drug, so the legitimate route for SS-31 (elamipretide) carries orphan-drug economics, not consumer-supplement pricing. This dimension scores the realistic biohacker channel, where users pay substantial money for likely subclinical dosing and uncertain product quality. For Barth patients with insurance access the math is medical-system dependent, but for self-directed SS-31 (elamipretide) use the spend is high and the expected payoff uncertain.
Effort is a real ongoing burden for SS-31 (elamipretide) because the legitimate route is daily subcutaneous self-injection. A user must handle sterile product, rotate sites, refrigerate material, manage sharps, and tolerate cold-chain friction when traveling. The injection itself takes minutes, but daily compliance plus site management raises the practical load well above oral options like creatine, CoQ10, or urolithin A. It is not IV-level extreme, yet the recurring nature makes the friction matter, especially for healthy users where the subjective payoff from SS-31 (elamipretide) is often unclear. That daily-injection requirement is a meaningful tax on adherence and a frequent reason cycles get abandoned.
SS-31 (elamipretide) can crowd out cheaper, more practical mitochondrial interventions, which is its opportunity-cost downside. Before reaching for gray-market SS-31 (elamipretide), most users should first optimize creatine, CoQ10 or ubiquinol, urolithin A, NAD+ support, magnesium, protein, zone-2 training, resistance work, sleep, and morning light. In diagnosed Barth syndrome the opportunity cost is low because Forzinity targets a disease-specific defect with no equivalent substitute. In speculative longevity use, the same budget can fund a broader, better-validated mitochondrial stack with far less legal, dosing, and sourcing uncertainty than SS-31 (elamipretide) carries. For most healthy users the cheaper foundational layer is not yet maxed out, which makes SS-31 (elamipretide) a premature and high-friction allocation of attention and money.
SS-31 (elamipretide) creates functional continuation, not addiction, so this downside is low. There is no verified withdrawal syndrome, no receptor downregulation pattern, no rebound, and no compulsive-use liability for SS-31 (elamipretide); a user can stop at any time without a physiological penalty beyond losing the effect. The only catch is that benefit is exposure-dependent: stop the daily injections and the cardiolipin-binding support simply fades as drug clears and membranes resume normal turnover. That is ordinary pharmacology, the same way a maintenance medication stops working when discontinued, not a dependency trap. For Barth syndrome the maintenance requirement is clinically acceptable; for healthy users it just means the cost and injection burden of SS-31 (elamipretide) persist as long as the effect is wanted, with no addictive hook pulling them back.
SS-31 (elamipretide) is highly reversible, the brightest spot on its downside ledger. It is not surgery, an implant, gene therapy, or any permanent tissue-altering procedure, and the literature shows no persistent legacy effects after stopping. The likely pattern after discontinuing SS-31 (elamipretide) is a return to baseline over days to weeks, with any injection-site irritation resolving separately. That cuts both ways: clean reversibility is good for safety but mirrors the weak durability of the upside. Serious hypersensitivity would demand immediate discontinuation and care, but routine SS-31 (elamipretide) exposure is otherwise among the more reversible peptide interventions a user could choose.
Is SS-31 (Elamipretide) worth it?
SS-31 (Elamipretide) is a 6.0 / 10 fit for people using mitochondrial, antioxidant, and cardiovascular as a measured experiment, not a belief-based staple. The best anchors are Zhao C et al. 2026, which reports approval-focused review: Barth syndrome rationale, crossover trial limitations, 168-week extension signal, injection-site reactions, and confirmatory trial requirement, and Birk AV et al. 2013, which reports mechanism paper showing SS-31 binds cardiolipin, protects cristae membranes, and accelerates ATP recovery after ischemia in preclinical kidney models. That gives SS-31 (Elamipretide) a real signal, but the report should stay narrow because responder fit, baseline status, and outcome tracking drive the practical value. Use SS-31 (Elamipretide) when the target is specific, measurable, and worth the tradeoff. Skip or stop SS-31 (Elamipretide) when the expected symptom, lab, or performance marker stays flat.
✅ Best for: Diagnosed Barth syndrome patients who qualify for prescription Forzinity, weigh at least 30 kg, and have specialist monitoring. Adults with genetically confirmed mitochondrial disease who can enroll in trials or access legitimate prescription-grade channels. Older adults with objective mitochondrial impairment, low ATPmax on 31P-MRS, low VO2max, sarcopenia, post-viral mitochondrial dysfunction, or similar markers who have already optimized lower-friction mitochondrial basics. Peptide-literate self-experimenters who understand that Karaa 2023 was negative for broad PMM and that FDA approval is Barth-specific.
❌ Avoid if: You are healthy and chasing generalized anti-aging without documented mitochondrial dysfunction. You would source from unverified research-chemical vendors without third-party identity, purity, and sterility data. You cannot tolerate daily subcutaneous injection, rotating sites, refrigeration, sharps, or the high injection-site-reaction burden. You are pregnant, nursing, under 30 kg, dealing with serious hypersensitivity history, working up peripheral neuropathy, or have severe renal impairment without clinician dosing support. Competitive athletes should verify status with GlobalDRO or their anti-doping authority and obtain medical/TUE guidance before use.
Sourcing & dosing caveat: gray-market supply; score assumes clean, correctly-dosed material.
What is SS-31 (Elamipretide) best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Mitochondrial: 8.5/10
Score: 8.5/10For mitochondrial, SS-31 (Elamipretide) earns 8.5/10 because the evidence points to a plausible use case without proving a universal response. Karaa A et al. 2023 is the best anchor here because it reports 218 participants and 40 mg/day subcutaneous elamipretide for 24 weeks did not improve 6MWT or fatigue versus placebo. Zhao C et al. 2026 adds context, but the exact mitochondrial outcome still needs baseline-matched tracking. That makes SS-31 (Elamipretide) most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop SS-31 (Elamipretide) if the expected change does not appear.
Antioxidant / Oxidative Stress: 6.0/10
Score: 6.0/10Mechanistically, SS-31 (Elamipretide) scores 6.0/10 for antioxidant because the evidence points to a plausible use case without proving a universal response. Ehlers JP et al. 2024 is the best anchor here because it reports 176 participants randomized and missed primary endpoints for low-luminance BCVA and GA area, with exploratory ellipsoid-zone and low-luminance letter-gain signals and injection-site. Karaa A et al. 2024 adds context, but the exact antioxidant outcome still needs baseline-matched tracking. That makes SS-31 (Elamipretide) most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop SS-31 (Elamipretide) if the expected change does not appear.
Cardiovascular: 5.5/10
Score: 5.5/10The cardiovascular case for SS-31 (Elamipretide) lands at 5.5/10 because the evidence points to a plausible use case without proving a universal response. Zhao C et al. 2026 is the best anchor here because it reports approval-focused review: Barth syndrome rationale, crossover trial limitations, 168-week extension signal, injection-site reactions, and confirmatory trial requirement. Birk AV et al. 2013 adds context, but the exact cardiovascular outcome still needs baseline-matched tracking. That makes SS-31 (Elamipretide) most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop SS-31 (Elamipretide) if the expected change does not appear.
Neuroprotection: 5.5/10
Score: 5.5/10Population fit explains the 5.5/10 neuroprotection score for SS-31 (Elamipretide) because the evidence points to a plausible use case without proving a universal response. Ehlers JP et al. 2024 is the best anchor here because it reports 176 participants randomized and missed primary endpoints for low-luminance BCVA and GA area, with exploratory ellipsoid-zone and low-luminance letter-gain signals and injection-site. Karaa A et al. 2024 adds context, but the exact neuroprotection outcome still needs baseline-matched tracking. That makes SS-31 (Elamipretide) most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop SS-31 (Elamipretide) if the expected change does not appear.
Geriatric / Aging Population: 5.5/10
Score: 5.5/10The main limitation behind SS-31 (Elamipretide)'s 5.5/10 geriatric score is that the evidence points to a plausible use case without proving a universal response. Ehlers JP et al. 2024 is the best anchor here because it reports 176 participants randomized and missed primary endpoints for low-luminance BCVA and GA area, with exploratory ellipsoid-zone and low-luminance letter-gain signals and injection-site. Karaa A et al. 2024 adds context, but the exact geriatric outcome still needs baseline-matched tracking. That makes SS-31 (Elamipretide) most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop SS-31 (Elamipretide) if the expected change does not appear.
Eye / Vision Health: 5.0/10
Score: 5.0/10For eye vision, SS-31 (Elamipretide) earns 5.0/10 because the evidence points to a plausible use case without proving a universal response. Ehlers JP et al. 2024 is the best anchor here because it reports 176 participants randomized and missed primary endpoints for low-luminance BCVA and GA area, with exploratory ellipsoid-zone and low-luminance letter-gain signals and injection-site. Karaa A et al. 2024 adds context, but the exact eye vision outcome still needs baseline-matched tracking. That makes SS-31 (Elamipretide) most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop SS-31 (Elamipretide) if the expected change does not appear.
Longevity / Lifespan: 5.0/10
Score: 5.0/10Mechanistically, SS-31 (Elamipretide) scores 5.0/10 for longevity because the evidence points to a plausible use case without proving a universal response. Ehlers JP et al. 2024 is the best anchor here because it reports 176 participants randomized and missed primary endpoints for low-luminance BCVA and GA area, with exploratory ellipsoid-zone and low-luminance letter-gain signals and injection-site. Karaa A et al. 2024 adds context, but the exact longevity outcome still needs baseline-matched tracking. That makes SS-31 (Elamipretide) most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop SS-31 (Elamipretide) if the expected change does not appear.
Healthspan: 5.0/10
Score: 5.0/10The healthspan case for SS-31 (Elamipretide) lands at 5.0/10 because the evidence points to a plausible use case without proving a universal response. Ehlers JP et al. 2024 is the best anchor here because it reports 176 participants randomized and missed primary endpoints for low-luminance BCVA and GA area, with exploratory ellipsoid-zone and low-luminance letter-gain signals and injection-site. Karaa A et al. 2024 adds context, but the exact healthspan outcome still needs baseline-matched tracking. That makes SS-31 (Elamipretide) most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop SS-31 (Elamipretide) if the expected change does not appear.
| Use Case | Score | Summary |
|---|---|---|
| ○ Kidney Function | 4.5 | Birk 2013 showed renal ischemia protection and ATP recovery in preclinical models; no positive human renal endpoint trial was verified. |
| ○ Energy / Fatigue | 4.5 | Restoring ETC efficiency should improve cellular energy production, but Nick's N=1 was neutral and Karaa 2023 did not confirm broad PMM fatigue benefit. |
| ○ Anti-Inflammatory | 4.0 | Reduces mitochondrial ROS-driven inflammatory signaling in the mechanism literature, but human inflammatory biomarker evidence is limited and not a primary clinical endpoint strength. |
| ○ Cellular Senescence | 4.0 | Mitochondrial dysfunction drives senescence biology, but SS-31 has no direct human senescence-marker trial and should not be treated as a senolytic or proven senomorphic compound. |
| ○ Muscle Growth / Hypertrophy | 3.5 | Improved mitochondrial function supports muscle bioenergetics, but no direct hypertrophy trial exists; the FDA approval is muscle strength in Barth syndrome, not muscle growth. |
| ○ Recovery / Repair | 3.5 | Enhanced cellular energy could support repair, yet no direct human recovery RCT was verified; evidence remains extrapolated from mitochondrial disease and ischemia-reperfusion models. |
| ○ Strength / Power | 3.0 | May support muscle function via bioenergetics, and Forzinity approval uses knee extensor strength, but healthy strength or athletic power evidence is not established. |
| ○ Cognition / Focus | 3.0 | The brain is mitochondria-dependent, but no verified human cognition RCT for SS-31 supports a higher score. This remains a mechanism-derived, not clinically proven, use case. |
| ○ Memory | 3.0 | Preclinical hippocampal protection is directionally relevant, but the audit found no human memory endpoint trial for SS-31 or elamipretide. |
| ○ Metabolic Health | 3.0 | Mitochondrial function underlies metabolic health, but direct human metabolic endpoint data are limited and no diabetes or insulin-sensitivity RCT drives this report. |
| ○ Traumatic Brain Injury | 3.0 | Preclinical traumatic brain injury models show mitochondrial stabilization and neuroprotection potential, but no human TBI trial was verified for SS-31. |
| ○ Autophagy | 3.0 | Mitophagy regulation may be influenced by cardiolipin stabilization, but no human autophagy-flux data were verified for elamipretide. |
| ○ Injury Recovery | 3.0 | Mitochondrial support aids tissue recovery in ischemia-reperfusion models, but human injury-recovery trials are absent. |
Frequently Asked Questions
How does SS-31 (elamipretide) actually work at the mitochondria?
SS-31 binds cardiolipin on the inner mitochondrial membrane and helps preserve cristae architecture and electron transport chain organization. Birk 2013 showed cardiolipin interaction in ischemic mitochondria, and Szeto 2014 summarizes the class. In practice, the target is real, but clinical benefit depends heavily on whether cardiolipin dysfunction is actually the bottleneck.
What did the Phase 3 MMPOWER-3 trial actually show?
Karaa 2023 showed that MMPOWER-3 missed both co-primary endpoints in primary mitochondrial myopathy: 6-minute walk distance and fatigue. The trial randomized 218 patients to 40 mg/day subcutaneous elamipretide or placebo for 24 weeks. That makes MMPOWER-3 the strongest broad-PMM negative readout and the main reason SS-31 stays in Worth Trying rather than Strong Recommend.
If MMPOWER failed, why did FDA approve Forzinity for Barth syndrome?
FDA approved Forzinity for Barth syndrome because Barth is a genetically defined cardiolipin-remodeling disease, and Forzinity improved knee extensor muscle strength as an intermediate endpoint. FDA's September 19, 2025 approval is accelerated, not broad traditional approval. Continued approval depends on a confirmatory trial showing clinical benefit. That authority signal applies to Barth syndrome patients weighing at least 30 kg, not general mitochondrial support.
Why did Nick stop using SS-31?
Nick stopped because the felt benefit did not clear the cost and injection burden. His review: "Great theory, expensive, didn't notice much. Ran it for a cycle, felt the injection-site reactions and the credit card pain more than any subjective mitochondrial lift." That matches the report's main practical warning: gray-market 5-10 mg/day use is much lower than the 40 mg/day clinical dose and still carries daily injection friction.
What is the difference between the biohacker dose and the trial dose?
The usual gray-market dose is 5-10 mg/day subcutaneous, while Forzinity and several clinical protocols use 40 mg/day. The lower community range is mostly cost-driven. Karaa 2023 tested 40 mg/day in PMM, and the Forzinity label lists 40 mg once daily for patients weighing at least 30 kg. Neutral N=1 results at 5 mg/day should not be treated as proof the approved dose fails in Barth syndrome.
Where does SS-31 come from and is gray-market sourcing safe?
Legitimate elamipretide is prescription Forzinity from regulated channels for Barth syndrome. Everything sold as SS-31 outside that pathway is a research-chemical product with buyer-managed risk: identity, purity, sterility, and potency can vary. This report scores the compound separately from supply chain, but practical users should not ignore sourcing. Require third-party identity and purity testing if you are outside a clinical trial or prescription channel.
Who should actually be on SS-31 vs who is just chasing wellness marketing?
The cleanest fit is diagnosed Barth syndrome under prescription care. The next research-relevant tier is documented mitochondrial disease or objective mitochondrial dysfunction with trial access. Karaa 2024 suggests genotype-defined PMM subgroups may matter, but it is post hoc. Healthy adults chasing generalized anti-aging sit in the weakest evidence tier, especially if they have not already optimized creatine, CoQ10 or ubiquinol, urolithin A, NAD+ support, and training.
How safe is SS-31 and what does it stack with?
SS-31 looks intrinsically clean in trials, but daily injection-site reactions are common and serious hypersensitivity is a Forzinity contraindication. Ehlers 2024 reported more side effects with elamipretide than placebo, mainly injection-site reactions. Mechanistic stacks include CoQ10 or ubiquinol, urolithin A, NAD+ precursors, creatine, zone-2 cardio, and strength training, but no RCT has tested the combined protocol.
What could change SS-31 (Elamipretide)'s score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Healthy-aging Phase 2 positive with a clear muscle-function effect | Efficacy 2.5 to 3.5; Evidence 3.0 to 3.5; Bioindividuality 2.0 to 3.0 | 6.0 / 10 👍 Worth trying |
| Confirmatory Barth trial fails and FDA withdraws accelerated approval | Evidence 3.0 to 2.0; Efficacy 2.5 to 2.0 | 5.0 / 10 ⚖️ Neutral |
| ReNEW Phase 3 dry AMD hits primary endpoint | Efficacy 2.5 to 3.5; Breadth 3.5 to 4.0; Evidence 3.0 to 3.5 | 6.1 / 10 👍 Worth trying |
| Barth or PMM receives full non-accelerated approval after confirmatory clinical-benefit data | Evidence 3.0 to 3.8; Efficacy 2.5 to 3.0 | 5.9 / 10 👍 Worth trying |
| Independent replication of the aged-muscle ATPmax signal succeeds in a human sarcopenia RCT | Efficacy 2.5 to 3.2; Bioindividuality 2.0 to 2.8; Evidence 3.0 to 3.3 | 5.8 / 10 👍 Worth trying |
| Long-term peripheral neuropathy signal is confirmed in post-market Forzinity surveillance | Side effects 3.0 to 4.0; Safety 1.5 to 2.5 | 5.3 / 10 ⚖️ Neutral |
Key Evidence Sources
- Ehlers JP et al. 2024 - ReCLAIM-2 randomized phase II trial in dry AMD. n=176 randomized; missed primary endpoints for low-luminance BCVA and GA area, with exploratory ellipsoid-zone and low-luminance letter-gain signals; injection-site reactions were common.
- Karaa A et al. 2024 - Genotype-specific post hoc MMPOWER-3 analysis. Post hoc analysis of n=218 parent trial; genotype-defined subgroups showed 6MWT signal, supporting enrichment rather than broad PMM efficacy.
- Karaa A et al. 2023 - MMPOWER-3 randomized clinical trial in primary mitochondrial myopathy. n=218; 40 mg/day subcutaneous elamipretide for 24 weeks did not improve 6MWT or fatigue versus placebo.
- FDA 2025 - Accelerated approval of Forzinity for Barth syndrome. FDA granted accelerated approval September 19, 2025 for Barth syndrome patients weighing at least 30 kg, based on knee extensor muscle strength as an intermediate endpoint.
- Forzinity Prescribing Information 2025 - Elamipretide label. 40 mg once daily subcutaneous dosing; renal dose reduction; serious hypersensitivity contraindication; benzyl alcohol neonatal warning; injection-site reactions common.
- Zhao C et al. 2026 - Elamipretide first cardiolipin-directed mitochondrial therapeutic for Barth syndrome. Approval-focused review: Barth syndrome rationale, crossover trial limitations, 168-week extension signal, injection-site reactions, and confirmatory trial requirement.
- Reid Thompson W et al. 2021 - Phase 2/3 Barth syndrome trial plus open-label extension. n=12 crossover trial missed primary endpoints at 12 weeks; open-label extension showed 6MWT and symptom improvements at 36 weeks.
- Thompson WR et al. 2024 - Long-term efficacy and safety of elamipretide in Barth syndrome. 168-week open-label extension of TAZPOWER; long-term 40 mg/day daily subcutaneous elamipretide in Barth syndrome.
- Van den Eynde J et al. 2023 - Identifying responders to elamipretide in Barth syndrome. Hierarchical clustering analysis in Barth syndrome; responder heterogeneity matters even within the best-fit disease population.
- Karaa A et al. 2018 - Randomized dose-escalation trial in primary mitochondrial myopathy. n=36; 5-day IV dose-escalation trial showed short-term 6MWT signal at high dose, later not confirmed by MMPOWER-3.
- Butler J et al. 2020 - PROGRESS-HF Phase 2 trial in HFrEF. n=71; 4 mg or 40 mg daily for 28 days was well tolerated but did not improve LVESV or LVEF compared with placebo.
- Daubert MA et al. 2017 - Randomized placebo-controlled elamipretide infusion trial in HFrEF. n=36; single IV infusion was well tolerated and high-dose cohort had favorable acute LV volume changes.
- Birk AV et al. 2013 - SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Mechanism paper showing SS-31 binds cardiolipin, protects cristae membranes, and accelerates ATP recovery after ischemia in preclinical kidney models.
- Szeto HH 2014 - First-in-class cardiolipin-protective compound review. Detailed mechanism and clinical-development review for cardiolipin-protective SS peptides.
- Siegel MP et al. 2013 - SS-31 improves mitochondrial energetics and skeletal muscle performance in aged mice. Aged-mouse study reported rapid restoration of in vivo mitochondrial energetics to young levels after SS-31.
- Mitchell W et al. 2020 - Mitochondrial protein interaction landscape of SS-31. Cross-linking mass spectrometry identified SS-31 interactors among cardiolipin-binding proteins involved in ATP production and 2-oxoglutarate metabolism.
- Mitochondrial Medicine Society 2017 - Patient care standards for primary mitochondrial disease. Consensus care standards emphasize supportive and organ-specific management; no broad society endorsement of SS-31 for general mitochondrial dysfunction was identified.
What does the evidence say about SS-31 (Elamipretide)?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Ehlers 2024, Karaa 2024, Karaa 2023, FDA 2025, Reid Thompson 2021, Butler 2020, Daubert 2017, Birk 2013, Szeto 2014, Siegel 2013
Pre-RCT-Era Pharmacology and Use
Confidence: Limited
Citations: Mitochondrial medicine standards 2017, Forzinity accelerated approval 2025
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for SS-31 (Elamipretide)
The lenses do not converge as strongly as they do for older practices or nutrients. Modern science identifies a precise mitochondrial target and a narrow approved disease use. Historical development shows the field repeatedly testing broader claims and then retreating toward responder-defined populations. Traditional medicine adds almost no compound-specific support. Honest synthesis: SS-31 is not a general vitality tonic. It is a specialized cardiolipin-targeting peptide with meaningful promise where cardiolipin pathology is documented.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Lactate Baseline (pre-protocol) During | Expected Down
- hs-CRP During | Expected Down
- ALT During | Expected Stable
- AST During | Expected Stable
- Creatinine During | Expected Stable
- eGFR During | Expected Stable
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Body During | Expected Up | Secondary
- Drive During | Expected Stable | Tertiary
Subjective Signals (Daily Voice Card)
- Fatigue Scale 1-5 | During | Expected Down
- Exercise Tolerance Scale 1-5 | During | Expected Up
- Injection-Site Irritation Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Injection-site infection
- New severe weakness or muscle pain
Other interventions for Mitochondrial
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.075 − 1.262 = 0.813
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.813 / 4.00) × 5 = 6.0 / 10
